Literature DB >> 30599052

Long-awaited treatment for hepatitis C virus decompensated cirrhosis.

Kiminori Kimura1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30599052     DOI： 10.1007/s00535-018-01538-6

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN： 0944-1174            Impact factor:   7.527


× No keyword cloud information.
  14 in total

Review 1.  Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies.

Authors:  Gennaro D'Amico; Guadalupe Garcia-Tsao; Luigi Pagliaro
Journal:  J Hepatol       Date:  2005-11-09       Impact factor: 25.083

2.  Safety and efficacy of an 8-week regimen of grazoprevir plus ruzasvir plus uprifosbuvir compared with grazoprevir plus elbasvir plus uprifosbuvir in participants without cirrhosis infected with hepatitis C virus genotypes 1, 2, or 3 (C-CREST-1 and C-CREST-2, part A): two randomised, phase 2, open-label trials.

Authors:  Edward J Gane; Stephen Pianko; Stuart K Roberts; Alexander J Thompson; Stefan Zeuzem; Eli Zuckerman; Ziv Ben-Ari; Graham R Foster; Kosh Agarwal; Alex L Laursen; Jan Gerstoft; Wei Gao; Hsueh-Cheng Huang; Brian Fitzgerald; Doreen Fernsler; Jerry J Li; Anjana Grandhi; Hong Liu; Feng-Hsiu Su; Shuyan Wan; Zhen Zeng; Huei-Ling Chen; Frank J Dutko; Bach-Yen T Nguyen; Janice Wahl; Michael N Robertson; Eliav Barr; Wendy W Yeh; Rebeca M Plank; Joan R Butterton; Rafael Esteban
Journal:  Lancet Gastroenterol Hepatol       Date:  2017-08-10

3.  Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy.

Authors:  Y Shiratori; F Imazeki; M Moriyama; M Yano; Y Arakawa; O Yokosuka; T Kuroki; S Nishiguchi; M Sata; G Yamada; S Fujiyama; H Yoshida; M Omata
Journal:  Ann Intern Med       Date:  2000-04-04       Impact factor: 25.391

4.  Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial.

Authors:  Xavier Forns; Samuel S Lee; Joaquin Valdes; Sabela Lens; Reem Ghalib; Humberto Aguilar; Franco Felizarta; Tarek Hassanein; Holger Hinrichsen; Diego Rincon; Rosa Morillas; Stefan Zeuzem; Yves Horsmans; David R Nelson; Yao Yu; Preethi Krishnan; Chih-Wei Lin; Jens J Kort; Federico J Mensa
Journal:  Lancet Infect Dis       Date:  2017-08-14       Impact factor: 25.071

5.  Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial.

Authors:  Masashi Mizokami; Osamu Yokosuka; Tetsuo Takehara; Naoya Sakamoto; Masaaki Korenaga; Hitoshi Mochizuki; Kunio Nakane; Hirayuki Enomoto; Fusao Ikeda; Mikio Yanase; Hidenori Toyoda; Takuya Genda; Takeji Umemura; Hiroshi Yatsuhashi; Tatsuya Ide; Nobuo Toda; Kazushige Nirei; Yoshiyuki Ueno; Yoichi Nishigaki; Juan Betular; Bing Gao; Akinobu Ishizaki; Masa Omote; Hongmei Mo; Kim Garrison; Phillip S Pang; Steven J Knox; William T Symonds; John G McHutchison; Namiki Izumi; Masao Omata
Journal:  Lancet Infect Dis       Date:  2015-04-08       Impact factor: 25.071

Review 6.  Liver cirrhosis.

Authors:  Detlef Schuppan; Nezam H Afdhal
Journal:  Lancet       Date:  2008-03-08       Impact factor: 79.321

7.  Efficacy of direct-acting antiviral treatment in patients with compensated liver cirrhosis: A multicenter study.

Authors:  Norio Itokawa; Masanori Atsukawa; Akihito Tsubota; Tadashi Ikegami; Noritomo Shimada; Keizo Kato; Hiroshi Abe; Tomomi Okubo; Taeang Arai; Ai-Nakagawa Iwashita; Chisa Kondo; Shigeru Mikami; Toru Asano; Yasushi Matsuzaki; Hidenori Toyoda; Takashi Kumada; Etsuko Iio; Yasuhito Tanaka; Katsuhiko Iwakiri
Journal:  Hepatol Res       Date:  2018-11-13       Impact factor: 4.288

8.  Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis.

Authors:  Michael P Curry; Jacqueline G O'Leary; Natalie Bzowej; Andrew J Muir; Kevin M Korenblat; Jonathan M Fenkel; K Rajender Reddy; Eric Lawitz; Steven L Flamm; Thomas Schiano; Lewis Teperman; Robert Fontana; Eugene Schiff; Michael Fried; Brian Doehle; Di An; John McNally; Anu Osinusi; Diana M Brainard; John G McHutchison; Robert S Brown; Michael Charlton
Journal:  N Engl J Med       Date:  2015-11-16       Impact factor: 91.245

9.  The safety and efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 1b infection.

Authors:  Stefan Zeuzem; Lawrence Serfaty; John Vierling; Wendy Cheng; Jacob George; Jan Sperl; Simone Strasser; Hiromitsu Kumada; Peggy Hwang; Michael Robertson; Janice Wahl; Eliav Barr; Rohit Talwani; Heather Platt
Journal:  J Gastroenterol       Date:  2018-01-17       Impact factor: 6.772

10.  Efficacy and safety of sofosbuvir-velpatasvir with or without ribavirin in HCV-infected Japanese patients with decompensated cirrhosis: an open-label phase 3 trial.

Authors:  Tetsuo Takehara; Naoya Sakamoto; Shuhei Nishiguchi; Fusao Ikeda; Tomohide Tatsumi; Yoshiyuki Ueno; Hiroshi Yatsuhashi; Yasuhiro Takikawa; Tatsuo Kanda; Minoru Sakamoto; Akihiro Tamori; Eiji Mita; Kazuaki Chayama; Gulan Zhang; Shampa De-Oertel; Hadas Dvory-Sobol; Takuma Matsuda; Luisa M Stamm; Diana M Brainard; Yasuhito Tanaka; Masayuki Kurosaki
Journal:  J Gastroenterol       Date:  2018-09-10       Impact factor: 7.527
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.